JH-X-119-01 (JH-X119-01) is a novel, potent, selective and covalent inhibitor of IRAK1 (interleukin-1 receptor-associated kinases 1) (IC50 = 9 nM) with anticancer activity.

IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC50 of 216 nM, is poorly active against JNK-1 and JNK-2 with IC50 of 3.801 μM, and >10 μM, respectively.

IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.

IRAK-1/4 Inhibitor is a novel inhibitor of interleukin-1 receptor-associated kinase (IRAK)-1/4.

Emavusertib (CA-4948) is a first-in-class, orally bioactive and highly potent IRAK4/FLT3 inhibtor (IC50 of < 50 nM) with anticancer activity.

IRAK-IN-6, formerly known as IRAK inhibitor 6, is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor.

IRAK4-IN-7 (CA-4948 analog; AU-4948) is a novel, potent, selective, and orally bioactive small molecule inhibitor of IRAK4 (interleukin-1 receptor-associated kinase 4) which has the potential to be used as a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling.

PF06650833 is a novel, potent and selective inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4) which is used to treat autoimmune diseases such as rheumatoid arthritis, lupus, and lymphomas.

Takinib is a novel, potent and selective TAK1 inhibitor with an IC50 of 9.5 nM.